[1]Zhuge Y, Liu Y, Xie W, et al. Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome. J Gastroenterol Hepatol,2019,34(4):634-642.
[2]李胤蒴,保洁,徐芸,等.16例吡咯烷生物碱相关肝窦阻塞综合征的临床病理分析.中华肝脏病杂志,2020,30(4):332-337.
[3]Mohty M, Malard F, Abecassis M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant,2016,51(7):906-912.
[4]Al Jefri AH, Abujazar H, Al-Ahmari A, et al. Veno-occlusive disease/sinusoidal obstruction syndrome after haematopoietic stem cell transplantation: Middle East/North Africa regional consensus on prevention, diagnosis and management. Bone Marrow Transplant,2017,52(4):588-591.
[5]Wang X, Qi X, Guo X. Tusanqi-related sinusoidal obstruction syndrome in China: A systematic review of the literatures. Medicine (Baltimore), 2015,94(23):e942.
[6]Yang XQ, Ye J, Li X, et al. Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: Pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes. World J Gastroenterol,2019,25(28):3753-3763.
[7]刘文成,李琰,常冰.吡咯生物碱相关肝窦阻塞综合征发病机制的研究进展.临床肝胆病杂志,2021,37(4):962-964.
[8]Ebmeyer J, Behrend J, Lorenz M, et al. Pyrrolizidine alkaloid-induced alterations of prostanoid synthesis in human endothelial cells. Chem Biol Interact, 2019,298:104-111.
[9]Harb R, Xie G, Lutzko C, et al. Bone marrow progenitor cells repair rat hepatic sinusoidal endothelial cells after liver injury. Gastroenterology, 2009,137(2):704-712.
[10] Moreira R, Pereira DM, Valentão P, et al. Pyrrolizidine alkaloids: Chemistry, pharmacology, toxicology and food safety. Int J Mol Sci,2018,19(6):1668.
[11] He Y, Shi M, Wu X, et al. Mutationalsignature analysis reveals widespread contribution of pyrrolizidine alkaloid exposure to human liver cancer. Hepatology, 2021[ahead of print].
[12] 朱成凯,张峰,诸葛宇征, 等.菊三七相关肝窦阻塞综合征115例的临床特征分析.中华消化杂志,2017,37(7):448-452.
[13] Zhuge YZ, Wang Y, Zhang F, et al. Clinical characteristics and treatment of pyrrolizidine alkaloid-related hepatic vein occlusive disease. Liver Int, 2018,38(10):1867-1874.
[14] Gao H, Li N, Wang JY, et al. Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids. J Dig Dis, 2012,13(1):33-39.
[15] Ma J, Xia Q, Fu PP, et al. Pyrrole-protein adducts - A biomarker of pyrrolizidine alkaloid-induced hepatotoxicity. J Food Drug Anal,2018,26(3):965-972.
[16] Gao H, Ruan JQ, Chen J, et al. Blood pyrrole-protein adducts as a diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome. Drug Des Devel Ther,2015,9:4861-4868.
[17] Ma J, Zhang W, He Y, et al. Clinical application of pyrrole-hemoglobin adducts as a biomarker of pyrrolizidine alkaloid exposure in humans. Arch Toxicol, 2021,95(2):759-765.
[18] Chan SS, Colecchia A, Duarte RF, et al. Imaging inhepatic veno-occlusive disease/sinusoidal obstruction syndrome. Biol Blood Marrow Transplant, 2020,26(10):1770-1779.
[19] 刘璐,张玮,张明, 等.吡咯生物碱相关肝窦阻塞综合征诊断"南京标准"的初步临床验证.中华消化杂志,2019,39(2):119-123.
[20] 陈依然,张玮,张明, 等.PA-HSOS严重度分级预测经颈静脉肝内门体分流术治疗PA-HSOS患者预后的研究.中华肝脏病杂志,2021,29(1):46-53.
[21] Cairo MS, Cooke KR, Lazarus HM,et al. Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS/VOD after haematopoietic cell transplantation. Br J Haematol,2020,190(6):822-836.
[22] Peng C, Zhang X, Zhang F, et al. Clinical efficacy and safety of anticoagulation therapy forpyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: a retrospective multicenter cohort study. Eur J Gastroenterol Hepatol, 2020,32(9):1168-1178.
[23] Wang Y, Qiao D, Li Y, et al. Risk factors for hepatic veno-occlusive disease caused by Gynura segetum: a retrospective study. BMC Gastroenterol, 2018,18(1):156.
[24] 董晓锋,王全楚,朱晓红, 等.抗凝溶栓治疗在土三七致肝小静脉闭塞中的应用和临床分析.肝脏,2018,23(11):985-987.
[25] 侯昌龙,许军,秦汉林, 等.经颈静脉肝内门体分流术治疗21例土三七相关肝窦阻塞综合征的疗效分析.中华消化杂志,2019,39(4):251-256.
[26] Xiao J, Tu J, Zhang H, et al. Risk factors of poor prognosis in patients with pyrrolidine alkaloid-induced hepatic sinusoidal obstruction syndrome after transjugular intrahepatic portosystemic shunt. Hepatol Int, 2021,[ahead of print].
[27] Ma J, Ruan J, Chen X, et al. Pyrrole-hemoglobin adducts, a more feasible potential biomarker of pyrrolizidine alkaloid exposure. Chem Res Toxicol, 2019,32(6):1027-1039.
[28] Trebicka J, Fernandez J, Papp M, et al. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. J Hepatol,2020,73(4):842-854. |
